Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1

被引：179

作者：

Na, Hye-Kyung ^{[1
]}

Surh, Young-Joon ^{[2
,3
,4
]}

机构：

[1] Sungshin Womens Univ, Coll Human Ecol, Dept Food & Nutr, Seoul 142732, South Korea

[2] Seoul Natl Univ, Coll Pharm, Tumor Microenvironm Global Core Res Inst, Seoul 151742, South Korea

[3] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 151742, South Korea

[4] Seoul Natl Univ, Canc Res Inst, Seoul 110744, South Korea

来源：

FREE RADICAL BIOLOGY AND MEDICINE | 2014年 / 67卷

基金：

新加坡国家研究基金会;

关键词：

Redox balance; Nrf2; Heme oxygenase-1; Adaptive survival response; Chemoresistance; Radioresistance; Antioxidant response elements; Free radicals; SQUAMOUS-CELL CARCINOMA; ZINC PROTOPORPHYRIN-IX; ACUTE MYELOID-LEUKEMIA; LUNG-CANCER CELLS; NF-KAPPA-B; OXIDATIVE STRESS; BREAST-CANCER; TUMOR-GROWTH; NF-E2-RELATED FACTOR-2; GENE-EXPRESSION;

D O I：

10.1016/j.freeradbiomed.2013.10.819

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Nuclear factor erythroid 2-related factor 2 (Nrf2) is an essential component of cellular defense against a vast variety of endogenous and exogenous insults, including oxidative stress. Nrf2 acts as a master switch in the circuits upregulating the expression of various stress-response proteins, especially heme oxygenase-1 (HO-1). Paradoxically, however, recent studies have demonstrated oncogenic functions of Nrf2 and its major target protein HO-1. Levels of Nrf2 and HO-1 are elevated in many different types of human malignancies, which may facilitate the remodeling of the tumor microenvironment making it advantageous for the autonomic growth of cancer cells, metastasis, angiogenesis, and tolerance to chemotherapeutic agents and radiation and photodynamic therapy. In this context, the cellular stress response or cytoprotective signaling mediated via the Nrf2-HO-1 axis is hijacked by cancer cells for their growth advantage and survival of anticancer treatment. Therefore, Nrf2 and HO-1 may represent potential therapeutic targets in the management of cancer. This review highlights the roles of Nrf2 and HO-1 in proliferation of cancer cells, their tolerance/resistance to anticancer treatments, and metastasis or angiogenesis in tumor progression. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：353 / 365

页数：13

共 145 条

[1] Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling [J].

Adam, Julie ;

Hatipoglu, Emine ;

O'Flaherty, Linda ;

Ternette, Nicola ;

Sahgal, Natasha ;

Lockstone, Helen ;

Baban, Dilair ;

Nye, Emma ;

Stamp, Gordon W. ;

Wolhuter, Kathryn ;

Stevens, Marcus ;

Fischer, Roman ;

Carmeliet, Peter ;

Maxwell, Patrick H. ;

Pugh, Chris W. ;

Frizzell, Norma ;

Soga, Tomoyoshi ;

Kessler, Benedikt M. ;

El-Bahrawy, Mona ;

Ratcliffe, Peter J. ;

Pollard, Patrick J. .

CANCER CELL, 2011, 20 (04) :524-537

[2] A New Model for Raf Kinase Inhibitory Protein Induced Chemotherapeutic Resistance [J].

Al-Mulla, Fahd ;

Bitar, Milad S. ;

Feng, Jingwei ;

Park, Sungdae ;

Yeung, Kam C. .

PLOS ONE, 2012, 7 (01)

[3] A Novel Experimental Heme Oxygenase-1-Targeted Therapy for Hormone-Refractory Prostate Cancer [J].

Alaoui-Jamali, Moulay A. ;

Bismar, Tarek A. ;

Gupta, Ajay ;

Szarek, Walter A. ;

Su, Jie ;

Song, Wei ;

Xu, Yingjie ;

Xu, Bin ;

Liu, Guoan ;

Vlahakis, Jason Z. ;

Roman, Gheorghe ;

Jiao, Jinsong ;

Schipper, Hyman M. .

CANCER RESEARCH, 2009, 69 (20) :8017-8024

[4] The Heme Oxygenase-1 Protein Is Overexpressed in Human Renal Cancer Cells following Activation of the Ras-Raf-ERK Pathway and Mediates Anti-Apoptotic Signal [J].

Banerjee, Pallavi ;

Basu, Aninda ;

Datta, Dipak ;

Gasser, Martin ;

Waaga-Gasser, Ana Maria ;

Pal, Soumitro .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (38) :33580-33590

[5] Bortezomib induces heme oxygenase-1 expression in multiple myeloma [J].

Barrera, Lawrence N. ;

Rushworth, Stuart A. ;

Bowles, Kristian M. ;

MacEwan, David J. .

CELL CYCLE, 2012, 11 (12) :2248-2252

[6] Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment [J].

Berberat, PO ;

Dambrauskas, Z ;

Gulbinas, A ;

Giese, T ;

Giese, N ;

Künzli, B ;

Autschbach, F ;

Meuer, S ;

Büchler, MW ;

Friess, H .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3790-3798

[7] The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[8] BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].

BOISE, LH ;

GONZALEZGARCIA, M ;

POSTEMA, CE ;

DING, LY ;

LINDSTEN, T ;

TURKA, LA ;

MAO, XH ;

NUNEZ, G ;

THOMPSON, CB .

CELL, 1993, 74 (04) :597-608

[9] Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers [J].

Chang, KW ;

Lee, TC ;

Yeh, WI ;

Chung, MY ;

Liu, CJ ;

Chi, LY ;

Lin, SC .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1551-1555

[10] Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways [J].

Chen, Qiang ;

Li, Wenjiao ;

Wan, Yunyan ;

Xia, Xiaochun ;

Wu, Qiao ;

Chen, Yanling ;

Lai, Zhide ;

Yu, Chundong ;

Li, Wengang .

HEPATOLOGY, 2012, 55 (06) :1820-1829

← 1 2 3 4 5 6 7 8 9 10 →